Bladder Cancer Clinical Practice Guidelines in Oncology NCCN Categories of Evidence and Consensus Category 1: The recommendation is based on high-level evidence (e.g., randomized controlled trials) and there is uniform NCCN consensus. Category 2A: The recommendation is based on lower-level evidence and there is uniform NCCN consensus. Category 2B: The recommendation is based on lower-level evidence and there is nonuniform NCCN consensus (but no major disagreement). Category 3: The recommendation is based on any level of evidence but reflects major disagreement. All recommendations are category 2A unless otherwise noted. Clinical trials: The NCCN believes that the best management for any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged. Overview An estimated 68,810 new cases of urinary bladder cancer will be diagnosed in the United States (51,230 men and 17,580 women) in 2008.1 Bladder cancer is the fourth most common cancer in men and is 3 times more common in men than in women in the United States. Furthermore, approximately 14,100 deaths (9950 men and 4150 women) from bladder cancer are anticipated.1 Bladder cancers are rarely diagnosed in individuals younger than 40 years. Because the median age at diagnosis is 65 years, medical comorbidities are a frequent consideration in patient management. The clinical spectrum of bladder cancer can be divided into 3 categories that differ in prognosis, management, and therapeutic aims. The first category consists of noninvasive tumors, for which treatment is directed at reducing recurrences and preventing progression to a more advanced stage. The...

If the inline PDF is not rendering correctly, you can download the PDF file here.

  • 1

    Jemal A, Siegel R, Ward E. Cancer statistics, 2008. CA Cancer J Clin 2008;76:7196.

  • 2

    Wasco MJ, Daignault S, Zhang Y. Urothelial carcinoma with divergent histologic differentiation (mixed histologic features) predicts the presence of locally advanced bladder cancer when detected at transurethral resection. Urology 2007;70:6974.

    • Search Google Scholar
    • Export Citation
  • 3

    Herr HW, Shipley WU, Bajorin DF. Cancer of the bladder. In: DeVita VT, Hellman S, Rosenberg SA, eds. Cancer: Principles and Practice of Oncology, 6th ed. Philadelphia: Lippincott Williams & Wilkins, 2001.

    • Search Google Scholar
    • Export Citation
  • 4

    Hall RR, Parmar MK, Richards AB, Smith PH. Changes in cystoscopic follow up in patients with bladder cancer and adjuvant intravesical chemotherapy. BMJ 1994;308:257260.

    • Search Google Scholar
    • Export Citation
  • 5

    Greene FL, Page DL, Fleming ID., eds. AJCC Cancer Staging Manual, 6th ed. New York: AJCC Springer-Verlag; 2002.

  • 6

    Montironi R, Lopez-Beltran A. The 2004 WHO classification of bladder tumors: a summary and commentary. Int J Surg Pathol 2005;13:143153.

  • 7

    Smith JA Jr, Labasky RF, Cockett AT. Bladder cancer clinical guidelines panel summary report on the management of nonmuscle invasive bladder cancer (stages Ta, T1, and TIS). J Urol 1999;162:16971701.

    • Search Google Scholar
    • Export Citation
  • 8

    Dutta SC, Smith JA Jr, Shappell SB. Clinical under staging of high risk nonmuscle invasive urothelial carcinoma treated with radical cystectomy. J Urol 2001;166:490493.

    • Search Google Scholar
    • Export Citation
  • 9

    Schwaibold HE, Sivalingam S, May F, Hartung R. The value of a second transurethral resection for T1 bladder cancer. BJU Int 2006;97:11991201.

  • 10

    Shelley MD, Kynaston H, Court J. A systematic review of intravesical bacillus Calmette-Guérin plus transurethral resection versus transurethral resection alone in Ta and T1 bladder cancer. BJU Int 2001;88:209216.

    • Search Google Scholar
    • Export Citation
  • 11

    Han RF, Pan JG. Can intravesical bacillus Calmette-Guérin reduce recurrence in patients with superficial bladder cancer? A meta-analysis of randomized trials. Urology 2006;67:12161223.

    • Search Google Scholar
    • Export Citation
  • 12

    Shelley MD, Wilt TJ, Court J. Intravesical bacillus Calmette-Guérin is superior to mitomycin C in reducing tumour recurrence in high-risk superficial bladder cancer: a meta-analysis of randomized trials. BJU Int 2004;93:485490.

    • Search Google Scholar
    • Export Citation
  • 13

    Bohle A, Jocham D, Bock PR. Intravesical bacillus Calmette-Guérin versus mitomycin C for superficial bladder cancer: a formal meta-analysis of comparative studies on recurrence and toxicity. J Urol 2003;169:9095.

    • Search Google Scholar
    • Export Citation
  • 14

    Lokeshwar VB, Habuchi T, Grossman HB. Bladder tumor markers beyond cytology: international consensus panel on bladder tumor markers. Urology 2005;66(Suppl 6A):3563.

    • Search Google Scholar
    • Export Citation
  • 15

    Herr H, Sogni PC. Does early cystectomy improve survival of patients with high-risk superficial bladder tumors? J Urol 2001;166:12961299.

  • 16

    Joudi FN, Smith BJ, O’Donnell MA. Final results from a national multicenter phase II trial of combination bacillus Calmette-Guérin plus interferon alpha-2B for reducing recurrence of superficial bladder cancer. Urol Oncol 2006;24:344348.

    • Search Google Scholar
    • Export Citation
  • 17

    Bohle A, Bock PR. Intravesical bacille Calmette-Guérin versus mitomycin C in superficial bladder cancer: formal meta-analysis of comparative studies on tumor progression. Urology 2004;63:682686; discussion 686–687.

    • Search Google Scholar
    • Export Citation
  • 18

    Shelley MD, Wilt TJ, Court J. Intravesical bacillus Calmette-Guérin is superior to mitomycin C in reducing tumour recurrence in high-risk superficial bladder cancer: a meta-analysis of randomized trials. BJU Int 2004;93:485490.

    • Search Google Scholar
    • Export Citation
  • 19

    Sylvester RJ, van der Meijden AP, Lamm DL. Intravesical bacillus Calmette-Guérin reduces the risk of progression in patients with superficial bladder cancer: a meta analysis of the published results of randomized clinical trials. J Urol 2002;168:19641970.

    • Search Google Scholar
    • Export Citation
  • 20

    Sylvester RJ, van der Meijden AP, Witjes JA, Kurth K. Bacillus Calmette-Guérin versus chemotherapy for the intravesical treatment of patients with carcinoma in situ of the bladder: a meta-analysis of the published results of randomized clinical trials. J Urol 2005;174:8691; discussion 91–82.

    • Search Google Scholar
    • Export Citation
  • 21

    Han RF, Pan JG. Can intravesical bacillus Calmette-Guérin reduce recurrence in patients with superficial bladder cancer? A meta-analysis of randomized trials. Urology 2006;67:12161223.

    • Search Google Scholar
    • Export Citation
  • 22

    Nieder AM, Brausi M, Lamm D. Management of stage T1 tumors of the bladder: International Consensus Panel. Urology 2006;66:108125.

  • 23

    Witjee JA. Management of BCG failures in superficial bladder cancer: a review. Eur Urol 2006;49:790797.

  • 24

    Kim B, Semelka RC, Ascher SM. Bladder tumor staging: comparison of contrast-enhanced CT, T1- and T2-weighted MR imaging, dynamic gadolinium-enchanced imaging, and late gadolinium-enhancing imaging. Radiology 1994;193:239245.

    • Search Google Scholar
    • Export Citation
  • 25

    Grossman HB, Natale RB, Tangen CM. Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. N Engl J Med 2003;349:859866.

    • Search Google Scholar
    • Export Citation
  • 26

    Sherif A, Holmberg L, Rintala E. Neoadjuvant cisplatinum based combination chemotherapy in patients with invasive bladder cancer: a combined analysis of two Nordic studies. Eur Urol 2004;45:297303.

    • Search Google Scholar
    • Export Citation
  • 27

    Winquist E, Kirchner TS, Segal R. Neoadjuvant chemotherapy for transitional cell carcinoma of the bladder: a systematic review and meta-analysis. J Urol 2004;171:561569.

    • Search Google Scholar
    • Export Citation
  • 28

    Juffs HG, Moore MJ, Tannock IF. The role of systemic chemotherapy in the management of muscle-invasive bladder cancer. Lancet Oncol 2002;3:738747.

    • Search Google Scholar
    • Export Citation
  • 29

    Lehmann J, Retz M, Wiemers C. Adjuvant cisplatin plus methotrexate versus methotrexate, vinblastine, epirubicin, and cisplatin in locally advanced bladder cancer: results of a randomized, multicenter, phase III trial (AUO-AB 05/95). J Clin Oncol 2005;23:49634974.

    • Search Google Scholar
    • Export Citation
  • 30

    Stöckle M, Meyenburg W, Wellek S. Advanced bladder cancer (stages pT3b, pT4a, pN1 and pN2): improved survival after radical cystectomy and 3 adjuvant cycles of chemotherapy. Results of a controlled prospective study. J Urol 1992;148:302307.

    • Search Google Scholar
    • Export Citation
  • 31

    Lehmann J, Franzaring L, Thüroff J. Complete long-term survival data from a trial of adjuvant chemotherapy vs control after radical cystectomy for locally advanced bladder cancer. BJU Int 2006;97:4247.

    • Search Google Scholar
    • Export Citation
  • 32

    Loehrer PJ Sr, Einhorn LH, Elson PJ. A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study. J Clin Oncol 1992;10:10661073.

    • Search Google Scholar
    • Export Citation
  • 33

    Lorusso V, Manzione L, de Vita F. Gemcitabine plus cisplatin for advanced transitional cell carcinoma of the urinary tract: a phase II multicenter trial. J Urol 2000;164:5356.

    • Search Google Scholar
    • Export Citation
  • 34

    Roberts JT, von der Maase H, Sengeløv L. Long-term survival results of a randomized trial comparing gemcitabine/cisplatin and methotrexate/vinblastine/doxorubicin/cisplatin in patients with locally advanced and metastatic bladder cancer. Ann Oncol 2006;17 (Suppl 5):v118122.

    • Search Google Scholar
    • Export Citation
  • 35

    Scher HI. Chemotherapy for invasive bladder cancer: neoadjuvant versus adjuvant. Semin Oncol 1990;17:555565.

  • 36

    Kata EJ, Herr H. The role of transurethral resection for muscle invasive bladder carcinoma [abstract]. J Urol 1993;149:Abstract 316A.

  • 37

    Sweeney P, Kursh ED, Resnick MI. Partial cystectomy. Urol Clin North Am 1992;19:701711.

  • 38

    Shipley WU, Winter KA, Kaufman DS. Phase III trial of neoadjuvant chemotherapy in patients with invasive bladder cancer treated with selective bladder preservation by combined radiation therapy and chemotherapy: initial results of RTOG 89-03. J Clin Oncol 1998;16:35763583.

    • Search Google Scholar
    • Export Citation
  • 39

    Shipley WU, Kaufman DS, Zehr E. Selective bladder preservation by combined modality protocol treatment: long-term outcomes of 190 patients with invasive bladder cancer. Urology 2002;60:6267.

    • Search Google Scholar
    • Export Citation
  • 40

    Russell KJ, Boileau MA, Higano C. Combined 5-fluorouracil and irradiation for transitional cell carcinoma of the urinary bladder. Int J Radiat Oncol Biol Phys 1990;19:693699.

    • Search Google Scholar
    • Export Citation
  • 41

    Russell KJ, Boileau MA, Ireton RC. Transitional cell carcinoma of the urinary bladder: histologic clearance with combined 5-FU chemotherapy and radiation therapy. Preliminary results of a bladder-preservation study. Radiology 1988;167:845848.

    • Search Google Scholar
    • Export Citation
  • 42

    Housset M, Maulard C, Chretien Y. Combined radiation and chemotherapy for invasive transitional-cell carcinoma of the bladder: a prospective study. J Clin Oncol 1993;11: 21502157.

    • Search Google Scholar
    • Export Citation
  • 43

    Orsatti M, Curotto A, Canobbio L. Alternating chemo-radiotherapy in bladder cancer: a conservative approach. Int J Radiat Oncol Biol Phys 1995;33:173178.

    • Search Google Scholar
    • Export Citation
  • 44

    Zietman AL, Shipley WU, Kaufman DS. A phase I/II trial of transurethral surgery combined with concurrent cisplatin, 5-fluorouracil and twice daily radiation followed by selective bladder preservation in operable patients with muscle invading bladder cancer. J Urol 1998;160:16731677.

    • Search Google Scholar
    • Export Citation
  • 45

    Kauffman D, Raghavan D, Carducci M. Phase II trial of gemcitabine plus cisplatin in patients with metastatic urothelial cancer. J Clin Oncol 2000;18:19211927.

    • Search Google Scholar
    • Export Citation
  • 46

    Sternberg CN, de Mulder PH, Schornagel JH. Randomized phase III trial of high-dose-intensity methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC) chemotherapy and recombinant human granulocyte colony-stimulating factor versus classic MVAC in advanced urothelial tract tumors: European Organization for Research and Treatment of Cancer protocol No. 30924. J Clin Oncol 2001;19:26382646.

    • Search Google Scholar
    • Export Citation
  • 47

    Von der Maase H, Hansen SW, Roberts JT. Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study. J Clin Oncol 2000;18:30683077.

    • Search Google Scholar
    • Export Citation
  • 48

    Lorusso V, Manzione L, de Vita F. Gemcitabine plus cisplatin for advanced transitional cell carcinoma of the urinary tract: a phase II multicenter trial. J Urol 2000;164:5356.

    • Search Google Scholar
    • Export Citation
  • 49

    Meluch AA, Greco FA, Burris HA III. Paclitaxel and gemcitabine chemotherapy for advanced transitional-cell carcinoma of the urothelial tract: a phase II trial of the Minnie pearl cancer research network. J Clin Oncol 2001;19:30183024.

    • Search Google Scholar
    • Export Citation
  • 50

    Dreicer R, Manola J, Schneider DJ. Phase II trial of gemcitabine and docetaxel in patients with advanced carcinoma of the urothelium: a trial of the Eastern Cooperative Oncology Group. Cancer 2003;97:27432747.

    • Search Google Scholar
    • Export Citation
  • 51

    Bellmunt J, Guillem V, Paz-Ares L. Phase I-II study of paclitaxel, cisplatin, and gemcitabine in advanced transitional-cell carcinoma of the urothelium. Spanish Oncology Genitourinary Group. J Clin Oncol 2000;18:32473255.

    • Search Google Scholar
    • Export Citation
  • 52

    Hussain M, Vaishampayan U, Du W. Combination paclitaxel, carboplatin, and gemcitabine is an active treatment for advanced urothelial cancer. J Clin Oncol 2001;19:25272533.

    • Search Google Scholar
    • Export Citation
  • 53

    Sweeney CJ, Roth BJ, Kabbinavar FF. Phase II study of pemetrexed for second-line treatment of transitional cell cancer of the urothelium. J Clin Oncol 2006;24:34513457.

    • Search Google Scholar
    • Export Citation
All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 297 121 7
PDF Downloads 154 81 8
EPUB Downloads 0 0 0